Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer
Condition: Rectal Cancer Intervention: Drug: Durvalumab (MEDI4736) Sponsors: Grupo Espanol Multidisciplinario del Cancer Digestivo; AstraZeneca; Vall d'Hebron Institute of Oncology (VHIO) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | Neoadjuvant Therapy | Rectal Cancers | Research